,characteristics,cell line,cell type,treatment,time point,strain
GSM4432378,Mock treated NHBE cells,NHBE,primary human bronchial epithelial cells,Mock treatment,24hrs after treatment,NA
GSM4432379,Mock treated NHBE cells,NHBE,primary human bronchial epithelial cells,Mock treatment,24hrs after treatment,NA
GSM4432380,Mock treated NHBE cells,NHBE,primary human bronchial epithelial cells,Mock treatment,24hrs after treatment,NA
GSM4432381,SARS-CoV-2 infected NHBE cells,NHBE,primary human bronchial epithelial cells,SARS-CoV-2 infected (MOI 2),NA,USA-WA1/2020
GSM4432382,SARS-CoV-2 infected NHBE cells,NHBE,primary human bronchial epithelial cells,SARS-CoV-2 infected (MOI 2),NA,USA-WA1/2020
GSM4432383,SARS-CoV-2 infected NHBE cells,NHBE,primary human bronchial epithelial cells,SARS-CoV-2 infected (MOI 2),NA,USA-WA1/2020
GSM4432384,Mock treated A549 cells,A549,Lung adenocarcinoma,Mock treatment,24hrs after treatment,NA
GSM4432385,Mock treated A549 cells,A549,Lung adenocarcinoma,Mock treatment,24hrs after treatment,NA
GSM4432386,Mock treated A549 cells,A549,Lung adenocarcinoma,Mock treatment,24hrs after treatment,NA
GSM4432387,SARS-CoV-2 infected A549 cells,A549,Lung adenocarcinoma,SARS-CoV-2 infected (MOI 0.2),NA,USA-WA1/2020
GSM4432388,SARS-CoV-2 infected A549 cells,A549,Lung adenocarcinoma,SARS-CoV-2 infected (MOI 0.2),NA,USA-WA1/2020
GSM4432389,SARS-CoV-2 infected A549 cells,A549,Lung adenocarcinoma,SARS-CoV-2 infected (MOI 0.2),NA,USA-WA1/2020
GSM4432390,Mock treated A549 cells,A549,Lung adenocarcinoma,Mock treatment,24hrs after treatment,NA
GSM4432391,Mock treated A549 cells,A549,Lung adenocarcinoma,Mock treatment,24hrs after treatment,NA
GSM4432392,RSV infected A549 cells,A549,Lung adenocarcinoma,RSV infected (MOI 15),NA,A2
GSM4432393,RSV infected A549 cells,A549,Lung adenocarcinoma,RSV infected (MOI 15),NA,A2
GSM4432394,Mock treated A549 cells,A549,Lung adenocarcinoma,Mock treatment,9hrs after treatment,NA
GSM4432395,Mock treated A549 cells,A549,Lung adenocarcinoma,Mock treatment,9hrs after treatment,NA
GSM4432396,IAV infected A549 cells,A549,Lung adenocarcinoma,IAV infected (MOI 5),NA,A/Puerto Rico/8/1934 (H1N1)
GSM4432397,IAV infected A549 cells,A549,Lung adenocarcinoma,IAV infected (MOI 5),NA,A/Puerto Rico/8/1934 (H1N1)
GSM4462336,Mock treated A549 cells,A549,Lung adenocarcinoma,Mock treatment,NA,NA
GSM4462337,Mock treated A549 cells,A549,Lung adenocarcinoma,Mock treatment,NA,NA
GSM4462338,Mock treated A549 cells,A549,Lung adenocarcinoma,Mock treatment,NA,NA
GSM4462339,SARS-CoV-2 infected A549 cells,A549,Lung adenocarcinoma,SARS-CoV-2 infected (MOI 2),NA,USA-WA1/2020
GSM4462340,SARS-CoV-2 infected A549 cells,A549,Lung adenocarcinoma,SARS-CoV-2 infected (MOI 2),NA,USA-WA1/2020
GSM4462341,SARS-CoV-2 infected A549 cells,A549,Lung adenocarcinoma,SARS-CoV-2 infected (MOI 2),NA,USA-WA1/2020
GSM4462342,Mock treated A549 cells trasnduced with a vector expressing human ACE2,A549,Lung adenocarcinoma,Mock treatment,NA,NA
GSM4462343,Mock treated A549 cells trasnduced with a vector expressing human ACE2,A549,Lung adenocarcinoma,Mock treatment,NA,NA
GSM4462344,Mock treated A549 cells trasnduced with a vector expressing human ACE2,A549,Lung adenocarcinoma,Mock treatment,NA,NA
GSM4462345,SARS-CoV-2 infected A549 cells trasnduced with a vector expressing human ACE2,A549,Lung adenocarcinoma,SARS-CoV-2 infected (MOI 0.2),NA,USA-WA1/2020
GSM4462346,SARS-CoV-2 infected A549 cells trasnduced with a vector expressing human ACE2,A549,Lung adenocarcinoma,SARS-CoV-2 infected (MOI 0.2),NA,USA-WA1/2020
GSM4462347,SARS-CoV-2 infected A549 cells trasnduced with a vector expressing human ACE2,A549,Lung adenocarcinoma,SARS-CoV-2 infected (MOI 0.2),NA,USA-WA1/2020
GSM4462348,Mock treated Calu-3 cells,Calu-3,Lung adenocarcinoma,Mock treatment,NA,NA
GSM4462349,Mock treated Calu-3 cells,Calu-3,Lung adenocarcinoma,Mock treatment,NA,NA
GSM4462350,Mock treated Calu-3 cells,Calu-3,Lung adenocarcinoma,Mock treatment,NA,NA
GSM4462351,SARS-CoV-2 infected Calu-3 cells,Calu-3,Lung adenocarcinoma,SARS-CoV-2 infected (MOI 2),NA,USA-WA1/2020
GSM4462352,SARS-CoV-2 infected Calu-3 cells,Calu-3,Lung adenocarcinoma,SARS-CoV-2 infected (MOI 2),NA,USA-WA1/2020
GSM4462353,SARS-CoV-2 infected Calu-3 cells,Calu-3,Lung adenocarcinoma,SARS-CoV-2 infected (MOI 2),NA,USA-WA1/2020
GSM4462354,Mock treated A549 cells,A549,Lung adenocarcinoma,Mock treatment,NA,NA
GSM4462355,Mock treated A549 cells,A549,Lung adenocarcinoma,Mock treatment,NA,NA
GSM4462356,Mock treated A549 cells,A549,Lung adenocarcinoma,Mock treatment,NA,NA
GSM4462357,RSV infected A549 cells,A549,Lung adenocarcinoma,RSV infected (MOI 2),NA,A2
GSM4462358,RSV infected A549 cells,A549,Lung adenocarcinoma,RSV infected (MOI 2),NA,A2
GSM4462359,RSV infected A549 cells,A549,Lung adenocarcinoma,RSV infected (MOI 2),NA,A2
GSM4462360,HPIV3 infected A549 cells,A549,Lung adenocarcinoma,HPIV3 infected (MOI 3),NA,JS
GSM4462361,HPIV3 infected A549 cells,A549,Lung adenocarcinoma,HPIV3 infected (MOI 3),NA,JS
GSM4462362,HPIV3 infected A549 cells,A549,Lung adenocarcinoma,HPIV3 infected (MOI 3),NA,JS
GSM4462363,Mock treated NHBE cells,NA,primary human bronchial epithelial cells,Mock treatment,12hrs after treatment,NA
GSM4462364,Mock treated NHBE cells,NA,primary human bronchial epithelial cells,Mock treatment,12hrs after treatment,NA
GSM4462365,Mock treated NHBE cells,NA,primary human bronchial epithelial cells,Mock treatment,12hrs after treatment,NA
GSM4462366,Mock treated NHBE cells,NA,primary human bronchial epithelial cells,Mock treatment,12hrs after treatment,NA
GSM4462367,IAV infected NHBE cells,NA,primary human bronchial epithelial cells,IAV infected (MOI 3),12hrs after treatment,A/Puerto Rico/8/1934 (H1N1)
GSM4462368,IAV infected NHBE cells,NA,primary human bronchial epithelial cells,IAV infected (MOI 3),12hrs after treatment,A/Puerto Rico/8/1934 (H1N1)
GSM4462369,IAV infected NHBE cells,NA,primary human bronchial epithelial cells,IAV infected (MOI 3),12hrs after treatment,A/Puerto Rico/8/1934 (H1N1)
GSM4462370,IAV infected NHBE cells,NA,primary human bronchial epithelial cells,IAV infected (MOI 3),12hrs after treatment,A/Puerto Rico/8/1934 (H1N1)
GSM4462371,IAVdNS1 infected NHBE cells,NA,primary human bronchial epithelial cells,IAVdNS1 infected (MOI 3),12hrs after treatment,A/Puerto Rico/8/1934 (H1N1) (dNS1)
GSM4462372,IAVdNS1 infected NHBE cells,NA,primary human bronchial epithelial cells,IAVdNS1 infected (MOI 3),12hrs after treatment,A/Puerto Rico/8/1934 (H1N1) (dNS1)
GSM4462373,IAVdNS1 infected NHBE cells,NA,primary human bronchial epithelial cells,IAVdNS1 infected (MOI 3),12hrs after treatment,A/Puerto Rico/8/1934 (H1N1) (dNS1)
GSM4462374,IAVdNS1 infected NHBE cells,NA,primary human bronchial epithelial cells,IAVdNS1 infected (MOI 3),12hrs after treatment,A/Puerto Rico/8/1934 (H1N1) (dNS1)
GSM4462375,human IFNB treated NHBE cells,NA,primary human bronchial epithelial cells,human IFNB treatment (100U/ml),4hrs after treatment,NA
GSM4462376,human IFNB treated NHBE cells,NA,primary human bronchial epithelial cells,human IFNB treatment (100U/ml),4hrs after treatment,NA
GSM4462377,human IFNB treated NHBE cells,NA,primary human bronchial epithelial cells,human IFNB treatment (100U/ml),6hrs after treatment,NA
GSM4462378,human IFNB treated NHBE cells,NA,primary human bronchial epithelial cells,human IFNB treatment (100U/ml),6hrs after treatment,NA
GSM4462379,human IFNB treated NHBE cells,NA,primary human bronchial epithelial cells,human IFNB treatment (100U/ml),12hrs after treatment,NA
GSM4462380,human IFNB treated NHBE cells,NA,primary human bronchial epithelial cells,human IFNB treatment (100U/ml),12hrs after treatment,NA
GSM4462413,Lung biopsy for heatly negative control,NA,Lung Biopsy,"No treatment - healthy 77 years old, male",NA,NA
GSM4462414,Lung biopsy for heatly negative control,NA,Lung Biopsy,"No treatment - healthy 72 years old, male",NA,NA
GSM4462415,Lung sample from postmortem COVID-19 patient,NA,Lung Biopsy,No treatment; >60 years old male COVID-19 deceased patient,NA,NA
GSM4462416,Lung sample from postmortem COVID-19 patient,NA,Lung Biopsy,No treatment; >60 years old male COVID-19 deceased patient,NA,NA
